This is still a low float stock, unless we see Emerald's shares beginning to hit the market, but I think they want to maintain a controlling position for strategic purposes.
It seems like a smart buyer took notice at LD Micro, bought a little, let the nervous-nellies out, and is back on the bid.
The company's June investor presentation on their homepage lays out a clear path to clinical trials for NB1111 with several newsworthy milestones highlighted over the next 12 months....I think the market will take notice as this company takes a smart strategic path to clinical trials for NB1111.....and there's good reason to believe there's other irons in the fire as well.
News 
Market Data 
Discover 
